Zepbound for Weight Loss
Zepbound is the weight-loss brand of tirzepatide, a once-weekly injection from Eli Lilly. It is the most effective weight-loss medication BeLite prescribes, and the one we reach for first when a patient wants the largest possible result or has not done well on other medications.
What Zepbound is
Tirzepatide activates two gut-hormone receptors, GLP-1 and GIP, that regulate appetite and how quickly food leaves the stomach. The practical effect is that patients feel full sooner, think about food less, and eat less without constant willpower. The FDA approved Zepbound for chronic weight management in November 2023 and for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024. The same molecule is sold as Mounjaro for type 2 diabetes.
What the trials showed
In the 72-week SURMOUNT-1 trial, adults without diabetes lost an average of 15% of their body weight on the 5 mg dose, 19.5% on 10 mg, and 20.9% on 15 mg, compared with 3.1% on placebo. In the first head-to-head trial against Wegovy (SURMOUNT-5, 2025), tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide over 72 weeks. We explain that trial in plain language in Zepbound vs. Wegovy: What the Head-to-Head Trial Shows. Three-year follow-up data also show improvements in blood pressure and cholesterol, covered in our SURMOUNT-1 cardiovascular post.
Who can benefit from Zepbound
Zepbound is indicated for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, high cholesterol, prediabetes, or sleep apnea. Zepbound should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and it is not combined with other GLP-1 medications. It is not used during pregnancy. If you take birth-control pills, the label advises a backup non-oral method for four weeks after starting and after each dose increase, because tirzepatide can reduce absorption of oral contraceptives.
How it is taken
- One injection under the skin once a week, any time of day, with or without food.
- Treatment starts at 2.5 mg and is increased in 2.5 mg steps no faster than every four weeks, up to a maximum of 15 mg. Most patients settle at a maintenance dose between 5 and 15 mg.
- If you miss a dose, take it within four days; otherwise skip it and resume your normal schedule. Never take two doses to catch up.
Side effects
The common side effects are digestive: nausea, diarrhea, constipation, and occasionally vomiting, mostly during the first weeks and after each dose increase. They usually fade as the body adjusts, and slowing the dose escalation controls them for most patients. Less common but more serious problems include pancreatitis and gallbladder disease; severe abdominal pain that does not go away should be reported the same day. Rapid weight loss on any medication takes some muscle along with fat, which is why we emphasize protein intake and resistance training — see How Much Muscle Do You Lose on GLP-1 Medications? and our full guide to Zepbound side effects.
Zepbound at BeLite
A BeLite medical provider reviews your history, blood pressure, and an EKG at the first visit before prescribing. Follow-up visits track your progress, adjust the dose, and manage side effects. Patients who want to step down from injections after reaching their goal can discuss the oral option Foundayo as a maintenance strategy.
Ready to find out which medication fits you? BeLite Medical Center’s medical providers have been prescribing weight-loss medication in Fairfax since 1995. Schedule online 24/7 at belitecom.simplybook.me or call or text (703) 359-9200. The consultation is free for new patients; the $150 new-patient fee applies only if you enroll.
Disclaimer
This page is general information, not medical advice. Whether any medication is right for you depends on your health history and can only be decided by a licensed medical provider after an evaluation. Prescription medications are prescribed only after an in-person visit at BeLite Medical Center, 3923 Blenheim Blvd, Suite 61A, Fairfax, VA 22030.
Sources (verified September 7, 2026)
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36. https://pubmed.ncbi.nlm.nih.gov/40353578/
Medications

Wegovy
The once-weekly semaglutide injection — the other leading GLP-1 for weight loss.

Foundayo
A once-daily GLP-1 pill with no food or water restrictions, approved in 2026.

Phentermine
An oral appetite suppressant with more than 60 years of use.































